Researchers at Mass General Brigham found that by December 2023, over one-third of all new prescriptions for type 2 diabetes were for GLP-1 receptor agonists, such as semaglutide or tirzepatide. New research shows a major shift in how weight loss…
Mounjaro Mania: New Diabetes Drug Takes Over As Old Treatments Fade
